Progress in the treatment of gastroesophageal reflux disease

doi:10.3877/cma.j.issn.2095-8773.2020.01.008

Abstract

Abstract:

Gastroesophageal reflux disease is a common symptom (or complication) caused by reflux of gastric contents. With the changes of peoples’ diet structure, the incidence of gastroesophageal reflux disease has been on the rise in recent years. Nowadays, the treatment methods for gastroesophageal reflux disease mainly include psychological intervention, drug therapy, endoscopic therapy, and surgical operation. The emergence of new technologies brings more hope for the treatment of esophageal reflux disease.

Key words: Gastroesophageal reflux disease, Psychological intervention, Drug therapy, Endoscope, Surgical operation

Jianfeng Xu, Junqing Zhou, Desheng Wei, Bing Wang, Linhai Fu, Zhupeng Li, Guangmao Yu. Progress in the treatment of gastroesophageal reflux disease[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2020, 07(01): 44-50.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2020.01.008

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2020/V07/I01/44

References 66

[1]	Tripathi M, Streutker C J, Marginean E C. Relevance of histology in the diagnosis of reflux esophagitis: Histology of reflux esophagitis[J]. Ann N Y Acad Sci，2018, 1434(1)：94-101.
[2]	Savarino E, De Bortoli N, De Cassan C, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review[J]. Dis Esophagus，2017，30(2)：1-9.
[3]	He J, Ma X, Zhao Y, et al. A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China[J]. BMC Gastroenterology, 2010, 10(1)：94.
[4]	Akyüz F, Mutluay Soyer Ö. How is gastroesophageal reflux disease classified[J]. Turk J Gastroenterol, 2017，28(Suppl 1)：S10-S11.
[5]	Ratcliffe E G, Jankowski J A. Gastroesophageal reflux disease and Barrett esophagus: an overview of evidence-based guidelines[J] . Pol Arch Intern Med, 2019, 129(7-8)：516-525.
[6]	Kamolz T, Pointier R, Velanovich V. The impact of gastroesophageal reflux disease on quality of life[J]. Surg Endosc, 2003, 17(8)：1193-1199.
[7]	Javadi S A H S, Shafikhani A A．Anxiety and depression in patients with gastroesophageal reflux disorder[J]. Electron physician, 2017, 9(8)：5107-5112.
[8]	Kimura Y, Kamiya T, Senoo K, et al. Persistent reflux symptoms cause anxiety, depression, and mental health and sleep disorders in gastroesophageal reflux disease patients[J]. J Clin Biochem Nutr, 2016, 59(1)：71-77.
[9]	Velanovich V, Karmy-Jones R. Psychiatric disorders affect outcomes of antireflux operations for gastroesophageal reflux disease[J]. Surg Endosc, 2001, 15(2)：171-175.
[10]	Bradley L A, Richter J E, Pulliam T J, et al. The relationship between stress and symptoms of gastroesophageal reflux: The influence of psychological factors[J]. Am J Gastroenterol, 1993, 88(1)：11-19.
[11]	Velanovich V, Karmy-Jones R. Psychiatric disorders affect outcomes of antireflux operations for gastroesophageal reflux disease[J]. Surg Endosc, 2001, 15(2)：171-175.
[12]	Watson D, Chan A, Myers J, et al. Illness behaviour influences the outcome of laparoscopic antireflux surgery[J]. J Am Coll Surg, 1997, 184(1)：44-48.
[13]	Coron E, Hatlebakk J G, Galmiche J P. Medical therapy of gastroesophageal reflux disease[J]. Curr Opin Gastroenterol, 2007, 23(4)：434-439.
[14]	Miner PB Jr. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux [J]. Aliment Pharmacol Ther, 2006, 23(s1)：25-32.
[15]	Tougas G, Armstrong D. Efficacy of H2 receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms[J]. Can J Gastroenterol, 1997, 11 Suppl B：51B-54B.
[16]	Sandhu D S, Fass R. Current trends in the management of gastroesophageal reflux disease[J]. Gut Liver, 2018, 12(1)：7-16.
[17]	Preston C, Donnellan C. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease[M]// Hoboken：John Wiley & Sons, Ltd, 2001.
[18]	Fock K M, Talley N, Goh K L, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett\" s oesophagus[J]. Gut, 2016, 65(9)：1402-1415.
[19]	Dean B B, Gano A D, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease[J]. Clin Gastroenterol Hepatol, 2004, 2(8)：656-664.
[20]	Khan Z, Alastal Y, Khan MA, et al.On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: a systematic review and meta-analysis[J]. Gastroenterol Res Pract, 2018, 2018：1-10.
[21]	Pace F, Porro G B. On-demand PPI therapy in GERD[J]. Curr Treat Options Gastroenterol, 2008, 11(1)：35-42.
[22]	Zvyaga T, Chang S Y, Chen C, et al. Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19[J]. Drug Metab Dispos, 2012, 40(9)：1698-1711.
[23]	Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date[J]. Therap Adv Gastroenterol, 2018, 11：1756283X1774577.
[24]	Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis[J]. Aliment Pharmacol Ther, 2015, 42(6)：685-695.
[25]	Iwakiri K, Umegaki E, Hiramatsu N, et al. Tu1059 a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20 mg once-daily) compared to lansoprazole (30 mg once-daily) in patients with erosive esophagitis[J]. Gastroenterology, 2014, 146(5)：S-741.
[26]	Umegaki E, Iwakiri K, Hiramatsu N, et al. Tu1052 a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to lansoprazole (15 mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis[J]. Gastroenterology, 2014, 146(5)：S-738.
[27]	Dettmar P W, Sykes J, Little S L, et al. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes [J]．Int J Clin Pract, 2006, 60(3)：275-283.
[28]	Pouchain D, Bigard M A, Liard F, et al. Gaviscon vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial[J]. BMC Gastroenterology, 2012, 12(1)：18.
[29]	De Ruigh A, Roman S, Chen J, et al. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study[J]. Aliment Pharmacol Ther, 2014, 40(5)：531-537.
[30]	Rohof W O, Bennink R J, Smout A J, et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease[J]. Clin Gastroenterol Hepatol, 2013, 11(12)：1585-1591.
[31]	Elsborg L, Beck B, Stubgaard M. Effect of sucralfate on gastroesophageal reflux in esophagitis[J]. Hepato-gastroenterology, 1985, 32(4)：181-184.
[32]	Hatlebakk J G. Pregnancy and drugs used in gastro-oesophageal reflux[J]. Prescrire Int, 2015, 24(166)：297.
[33]	Vãlean S, Petrescu M, C？tinean A, et al. Pill esophagitis[J]. Rom J Gastroenterol, 2005, 14(2)：159-163.
[34]	Reddy A N, Budhraja M．Sucralfate therapy for lye-induced esophagitis[J]. Am J Gastroenterol, 1988, 83(1)：71-73.
[35]	Fuchs K H, Babic B, Breithaupt W, et al. EAES recommendations for the management of gastroesophageal reflux disease[J]. Surg Endosc, 2014, 28(6)：1753-1773.
[36]	Arana A, Johannes C B, McQuay L J, et al.Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case-control study[J]．Drug Saf, 2015, 38(12)：1187-1199.
[37]	Lowe R C, Wolfe M M. The pharmacological management of gastroesophageal reflux disease[J]. Minerva Gastroenterol Dietol, 2004, 50(3)：227-237.
[38]	Mizuta Y, Shikuwa S, Isomoto H, et al. Recent insights into digestive motility in functional dyspepsia[J]．J Gastroenterol, 2006, 41(11)：1025-1040.
[39]	Ruth M, Hamelin B, Röhss K, et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease[J]. Aliment Pharmacol Ther, 1998, 12(1)：35-40.
[40]	Chun B J, Lee D S. The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease[J]. Eur Arch Otorhinolaryngol, 2013, 270(4)：1385-1390.
[41]	Zeng J, Zuo X L, Li Y Q, et al. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study[J]. Eur J Clin Pharmacol, 2007, 63(6)：529-536.
[42]	Mertens V, Blondeau K, Pauwels A, et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients[J]. Dig Dis Sci，2009, 54(5)：972-979.
[43]	Koek, H G. Effect of the GABAB agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors[J]. Gut, 2003, 52(10)：1397-1402.
[44]	Emmitte K A. MGlu5 negative allosteric modulators: A patent review (2010-2012)[J]. Expert Opin Ther Pat, 2013, 23(4)：393-408.
[45]	Ostovaneh M R, Saeidi B, Hajifathalian K, et al. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial[J]. Neurogastroenterol Motil, 2014, 26(5)：670-678.
[46]	Viazis N, Keyoglou A, Kanellopoulos A K, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study[J]. Am J Gastroenterol, 2012, 107(11)：1662-1667.
[47]	Limsrivilai J, Charatcharoenwitthaya P, Pausawasdi N, et al. Imipramine for treatment of esophageal hypersensitivity and functional heartburn: a randomized placebo-controlled trial[J]. Am J Gastroenterol，2016, 111(2)：217-224.
[48]	Tominaga K, Fujiwara Y, Shimoyama Y, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan[J]. J Gastroenterol, 2012, 47(3)：284-292.
[49]	Wendling M R, Melvin W S, Perry K A. Impact of transoral incisionless fundoplication (TIF) on subjective and objective GERD indices: a systematic review of the published literature[J]. Surg Endosc, 2013, 27(10)：3754-3761.
[50]	Fass R, Cahn F, Scotti D J, et al. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease[J]. Surg Endosc, 2017, 31(12)：4865-4882.
[51]	Liang W T, Wang Z G, Wang F, et al. Long-term outcomes of patients with refractory gastroesophageal reflux disease following a minimally invasive endoscopic procedure: a prospective observational study[J]. BMC Gastroenterol, 2014, 14(1)：178.
[52]	Inoue H, Ito H, Ikeda H, et al. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: A pilot study[J]. Ann Gastroenterol, 2014, 27(4)：346-351.
[53]	Robertson A G, Patel R N, Couper G W, et al. Long-term outcomes following laparoscopic anterior and Nissen fundoplication[J]. ANZ J Surg, 2017, 87(4)：300-304.
[54]	Omura N, Yano F, Tsuboi K, et al. Surgical results of laparoscopic Toupet fundoplication for gastroesophageal reflux disease with special reference to recurrence[J]. Esophagus，2018，5(4)：217-223.
[55]	Yano F, Omura N, Tsuboi K, et al. Laparoscopic Collis gastroplasty and Dor fundoplication for reflux esophagitis complicated by a penetrating ulcer and shortened esophagus: a case report[J]. Surg Laparosc Endosc Percutan Tech，2007, 17(4)：322-324.
[56]	Richter J, Kumar A, Lipka S, et al. Efficacy of laparoscopic Nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis[J]. Gastroenterology, 2018，154(5)：1298-1308.
[57]	Tan G, Yang Z, Wang Z. Meta-analysis of laparoscopic total (Nissen) versus posterior (Toupet) fundoplication for gastro-oesophageal disease based on randomized clinical trials[J]. ANZ J Surg, 2011, 81(4)：246-252.
[58]	Roks D J, Koetje J H, Oor J E, et al. Randomized clinical trial of 270° posterior versus 180° anterior partial laparoscopic fundoplication for gastro-oesophageal reflux disease[J]. Br J Surg, 2017, 104(7)：843-851.
[59]	Ganz R A. A Modern magnetic implant for gastroesophageal reflux disease (GERD)[J]. Clin Gastroenterol Hepatol, 2016, 15(9)：1326-1337.
[60]	Lipham J C, Taiganides P A, Louie B E, et al. Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease[J]. Dis Esophagus, 2015, 28(4)：305-311.
[61]	Skubleny D, Switzer N J, Dang J, et al. LINX^® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis[J]. Surg Endosc, 2017, 31(8)：3078-3084.
[62]	Kappelle W F, Bredenoord A J, Conchillo J M, et al. Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease - interim results of an international multicentre trial[J]. Aliment Pharmacol Ther, 2015, 42(5)：614-625.
[63]	Rodríguez L, Rodriguez P, Gómez B, et al. Long-term results of electrical stimulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease[J]. Endoscopy, 2013, 45(8)：595-604.
[64]	Rodríguez L, Rodriguez P A, Gómez B, et al. Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: long-term 3-year results[J]. Surg Endosc, 2016, 30(7)：2666-2672.
[65]	Madalosso C A, Gurski R R, Callegari-Jacques S M, et al. The impact of gastric bypass on gastroesophageal reflux disease in morbidly obese patients[J]. Ann Surg, 2016, 263(1)：110.
[66]	Holmberg D, Santoni G, Xie S, et al. Gastric bypass surgery in the treatment of gastro-oesophageal reflux symptoms[J]. Aliment Pharmacol Ther, 2019, 50(2)：159-166.

Please choose a citation manager

Content to export